checkAd
    Orchestra BioMed Holdings Aktie
    5,1000
     
    USD
    -8,11 %
    -0,4500 USD
    Letzter Kurs 04.05.24 Nasdaq
    4,9900
     
    USD
    900 STK
    Geldkurs 03.05.24
    5,1100
     
    USD
    1.000 STK
    Briefkurs 03.05.24
    ISIN: US68572M1062 · WKN: A3D6DV · SYM: OBIO · USA

    Neueste Nachrichten

    Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
    30.04.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
    30.04.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
    27.03.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
    26.03.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
    13.03.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed to Participate in Upcoming Investor Conferences
    07.03.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
    06.03.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years
    26.02.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients
    08.01.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
    13.11.23 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed to Present at Upcoming Investor Conferences
    09.11.23 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT for the Treatment of Hypertension in Pacemaker Patients
    19.09.23 · globenewswire · Orchestra BioMed Holdings